Trial Outcomes & Findings for Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma (NCT NCT02303041)
NCT ID: NCT02303041
Last Updated: 2019-01-29
Results Overview
Response was assessed by the Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 criteria, and reported as overall response rate (ORR), comprised of the sum of complete response (CR) rate and partial response (PR) rate. * Complete Response (CR) = Disappearance of all target lesions * Partial Response (PR) = ≥ 30% decrease in the sum of the longest diameter of target lesions * Overall Response (OR) = CR + PR
Recruitment status
TERMINATED
Study phase
PHASE2
Target enrollment
10 participants
Primary outcome timeframe
Up to 2 years
Results posted on
2019-01-29
Participant Flow
Participant milestones
| Measure |
BCC Smoothened Inhibitor-naive
Participants with locally advanced or metastatic basal cell carcinoma (BCC) and naive to treatment with Smoothened inhibitors receive sonidegib and buparlisib in repeating 28-day cycles in the absence of disease progression or unacceptable toxicity.
Buparlisib: Administered orally at starting dose of 80 mg/day
Sonidegib: Administered orally at starting dose of 200 mg/day
|
BCC Refractory or Relapsed After Smoothened Inhibitor
Participants with locally advanced or metastatic basal cell carcinoma (BCC) that is refractory or relapsed after treatment with Smoothened inhibitors receive sonidegib and buparlisib in repeating 28-day cycles in the absence of disease progression or unacceptable toxicity.
Buparlisib: Administered orally at starting dose of 80 mg/day
Sonidegib: Administered orally at starting dose of 200 mg/day
|
|---|---|---|
|
Overall Study
STARTED
|
4
|
6
|
|
Overall Study
COMPLETED
|
3
|
4
|
|
Overall Study
NOT COMPLETED
|
1
|
2
|
Reasons for withdrawal
| Measure |
BCC Smoothened Inhibitor-naive
Participants with locally advanced or metastatic basal cell carcinoma (BCC) and naive to treatment with Smoothened inhibitors receive sonidegib and buparlisib in repeating 28-day cycles in the absence of disease progression or unacceptable toxicity.
Buparlisib: Administered orally at starting dose of 80 mg/day
Sonidegib: Administered orally at starting dose of 200 mg/day
|
BCC Refractory or Relapsed After Smoothened Inhibitor
Participants with locally advanced or metastatic basal cell carcinoma (BCC) that is refractory or relapsed after treatment with Smoothened inhibitors receive sonidegib and buparlisib in repeating 28-day cycles in the absence of disease progression or unacceptable toxicity.
Buparlisib: Administered orally at starting dose of 80 mg/day
Sonidegib: Administered orally at starting dose of 200 mg/day
|
|---|---|---|
|
Overall Study
Adverse Event
|
1
|
2
|
Baseline Characteristics
Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma
Baseline characteristics by cohort
| Measure |
BCC Smoothened Inhibitor-naive
n=4 Participants
Participants with locally advanced or metastatic basal cell carcinoma (BCC) and naive to treatment with Smoothened inhibitors receive sonidegib and buparlisib in repeating 28-day cycles in the absence of disease progression or unacceptable toxicity.
Buparlisib: Administered orally at starting dose of 80 mg/day
Sonidegib: Administered orally at starting dose of 200 mg/day
|
BCC Refractory or Relapsed After Smoothened Inhibitor
n=6 Participants
Participants with locally advanced or metastatic basal cell carcinoma (BCC) that is refractory or relapsed after treatment with Smoothened inhibitors receive sonidegib and buparlisib in repeating 28-day cycles in the absence of disease progression or unacceptable toxicity.
Buparlisib: Administered orally at starting dose of 80 mg/day
Sonidegib: Administered orally at starting dose of 200 mg/day
|
Total
n=10 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
2 Participants
n=5 Participants
|
4 Participants
n=7 Participants
|
6 Participants
n=5 Participants
|
|
Age, Categorical
>=65 years
|
2 Participants
n=5 Participants
|
2 Participants
n=7 Participants
|
4 Participants
n=5 Participants
|
|
Age, Continuous
|
72.3 years
STANDARD_DEVIATION 20.9 • n=5 Participants
|
60.7 years
STANDARD_DEVIATION 8.01 • n=7 Participants
|
61.2 years
STANDARD_DEVIATION 14.3 • n=5 Participants
|
|
Sex: Female, Male
Female
|
2 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
2 Participants
n=5 Participants
|
|
Sex: Female, Male
Male
|
2 Participants
n=5 Participants
|
6 Participants
n=7 Participants
|
8 Participants
n=5 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
4 Participants
n=5 Participants
|
6 Participants
n=7 Participants
|
10 Participants
n=5 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Black or African American
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
White
|
4 Participants
n=5 Participants
|
6 Participants
n=7 Participants
|
10 Participants
n=5 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Region of Enrollment
United States
|
4 participants
n=5 Participants
|
6 participants
n=7 Participants
|
10 participants
n=5 Participants
|
PRIMARY outcome
Timeframe: Up to 2 yearsResponse was assessed by the Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 criteria, and reported as overall response rate (ORR), comprised of the sum of complete response (CR) rate and partial response (PR) rate. * Complete Response (CR) = Disappearance of all target lesions * Partial Response (PR) = ≥ 30% decrease in the sum of the longest diameter of target lesions * Overall Response (OR) = CR + PR
Outcome measures
| Measure |
BCC Smoothened Inhibitor-naive
n=3 Participants
Participants with locally advanced or metastatic basal cell carcinoma (BCC) and naive to treatment with Smoothened inhibitors receive sonidegib and buparlisib in repeating 28-day cycles in the absence of disease progression or unacceptable toxicity.
Buparlisib: Administered orally at starting dose of 80 mg/day
Sonidegib: Administered orally at starting dose of 200 mg/day
|
BCC Refractory or Relapsed After Smoothened Inhibitor
n=4 Participants
Participants with locally advanced or metastatic basal cell carcinoma (BCC) that is refractory or relapsed after treatment with Smoothened inhibitors receive sonidegib and buparlisib in repeating 28-day cycles in the absence of disease progression or unacceptable toxicity.
Buparlisib: Administered orally at starting dose of 80 mg/day
Sonidegib: Administered orally at starting dose of 200 mg/day
|
|---|---|---|
|
Overall Response Rate (ORR)
|
0 Participants
|
1 Participants
|
SECONDARY outcome
Timeframe: up to 12 weeksPopulation: Most participants were not evaluable per protocol.
Response per the Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 criteria was monitored for duration of response (DOR) * Complete Response (CR) = Disappearance of all target lesions * Partial Response (PR) = ≥ 30% decrease in the sum of the longest diameter of target lesions * Overall Response (OR) = CR + PR * Progressive disease (PD) = 20% increase in the sum of the longest diameter of target lesions * Stable disease (SD) = Small changes that do not meet any of the above criteria
Outcome measures
| Measure |
BCC Smoothened Inhibitor-naive
Participants with locally advanced or metastatic basal cell carcinoma (BCC) and naive to treatment with Smoothened inhibitors receive sonidegib and buparlisib in repeating 28-day cycles in the absence of disease progression or unacceptable toxicity.
Buparlisib: Administered orally at starting dose of 80 mg/day
Sonidegib: Administered orally at starting dose of 200 mg/day
|
BCC Refractory or Relapsed After Smoothened Inhibitor
n=1 Participants
Participants with locally advanced or metastatic basal cell carcinoma (BCC) that is refractory or relapsed after treatment with Smoothened inhibitors receive sonidegib and buparlisib in repeating 28-day cycles in the absence of disease progression or unacceptable toxicity.
Buparlisib: Administered orally at starting dose of 80 mg/day
Sonidegib: Administered orally at starting dose of 200 mg/day
|
|---|---|---|
|
Median Duration of Response
|
—
|
13.8 months
Interval 13.8 to 13.8
|
SECONDARY outcome
Timeframe: Up to 30 days post-treatmentAdverse events, graded according to the National Cancer Institute CTCAE version 3.0, are reported by treatment arm in total and by Grade 1 to 5.
Outcome measures
| Measure |
BCC Smoothened Inhibitor-naive
n=4 Participants
Participants with locally advanced or metastatic basal cell carcinoma (BCC) and naive to treatment with Smoothened inhibitors receive sonidegib and buparlisib in repeating 28-day cycles in the absence of disease progression or unacceptable toxicity.
Buparlisib: Administered orally at starting dose of 80 mg/day
Sonidegib: Administered orally at starting dose of 200 mg/day
|
BCC Refractory or Relapsed After Smoothened Inhibitor
n=6 Participants
Participants with locally advanced or metastatic basal cell carcinoma (BCC) that is refractory or relapsed after treatment with Smoothened inhibitors receive sonidegib and buparlisib in repeating 28-day cycles in the absence of disease progression or unacceptable toxicity.
Buparlisib: Administered orally at starting dose of 80 mg/day
Sonidegib: Administered orally at starting dose of 200 mg/day
|
|---|---|---|
|
Adverse Event Frequency
All adverse events
|
49 adverse events
|
81 adverse events
|
|
Adverse Event Frequency
Grade 1 (mild)
|
30 adverse events
|
43 adverse events
|
|
Adverse Event Frequency
Grade 2 (moderate)
|
16 adverse events
|
33 adverse events
|
|
Adverse Event Frequency
Grade 3 (severe)
|
3 adverse events
|
5 adverse events
|
|
Adverse Event Frequency
Grade 4 (life-threatening)
|
0 adverse events
|
0 adverse events
|
|
Adverse Event Frequency
Grade 5 (fatal)
|
0 adverse events
|
0 adverse events
|
SECONDARY outcome
Timeframe: Baseline to 2 yearsPopulation: The individual samples were not analyzed for the biomarkers due to the overall small sample size.
Immunostaining for the Gli-1; Gli-2; "Patched" (Ptch) ; "Suppressor of Fused" (SuFu); "Smoothened" (Smo)"; and phosphatidylinositol-3-kinase (PI3K) cellular biomarkers were to be contacted at baseline and after 12 weeks of treatment.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: up to 2 years post-treatmentPopulation: The individual samples were not analyzed for the biomarkers due to the overall small sample size, and thus the correlation of gene expression profile to therapeutic response was not conducted.
The gene expression profiles for Gli-1; Gli-2; "Patched" (Ptch) ; "Suppressor of Fused" (SuFu); "Smoothened" (Smo)"; and phosphatidylinositol-3-kinase (PI3K) were to be correlated to the clinical response to therapeutic therapy.
Outcome measures
Outcome data not reported
Adverse Events
BCC Smoothened Inhibitor-naive
Serious events: 0 serious events
Other events: 4 other events
Deaths: 0 deaths
BCC Refractory or Relapsed After Smoothened Inhibitor
Serious events: 2 serious events
Other events: 6 other events
Deaths: 0 deaths
Serious adverse events
| Measure |
BCC Smoothened Inhibitor-naive
n=4 participants at risk
Participants with locally advanced or metastatic basal cell carcinoma (BCC) and naive to treatment with Smoothened inhibitors receive sonidegib and buparlisib in repeating 28-day cycles in the absence of disease progression or unacceptable toxicity.
Buparlisib: Administered orally at starting dose of 80 mg/day
Sonidegib: Administered orally at starting dose of 200 mg/day
|
BCC Refractory or Relapsed After Smoothened Inhibitor
n=6 participants at risk
Participants with locally advanced or metastatic basal cell carcinoma (BCC) that is refractory or relapsed after treatment with Smoothened inhibitors receive sonidegib and buparlisib in repeating 28-day cycles in the absence of disease progression or unacceptable toxicity.
Buparlisib: Administered orally at starting dose of 80 mg/day
Sonidegib: Administered orally at starting dose of 200 mg/day
|
|---|---|---|
|
Gastrointestinal disorders
Abdominal pain
|
0.00%
0/4 • 2 years
|
16.7%
1/6 • Number of events 1 • 2 years
|
|
Investigations
Alanine aminotransferase increase
|
0.00%
0/4 • 2 years
|
16.7%
1/6 • Number of events 1 • 2 years
|
Other adverse events
| Measure |
BCC Smoothened Inhibitor-naive
n=4 participants at risk
Participants with locally advanced or metastatic basal cell carcinoma (BCC) and naive to treatment with Smoothened inhibitors receive sonidegib and buparlisib in repeating 28-day cycles in the absence of disease progression or unacceptable toxicity.
Buparlisib: Administered orally at starting dose of 80 mg/day
Sonidegib: Administered orally at starting dose of 200 mg/day
|
BCC Refractory or Relapsed After Smoothened Inhibitor
n=6 participants at risk
Participants with locally advanced or metastatic basal cell carcinoma (BCC) that is refractory or relapsed after treatment with Smoothened inhibitors receive sonidegib and buparlisib in repeating 28-day cycles in the absence of disease progression or unacceptable toxicity.
Buparlisib: Administered orally at starting dose of 80 mg/day
Sonidegib: Administered orally at starting dose of 200 mg/day
|
|---|---|---|
|
Metabolism and nutrition disorders
Anorexia
|
25.0%
1/4 • Number of events 1 • 2 years
|
0.00%
0/6 • 2 years
|
|
Gastrointestinal disorders
Abdominal pain
|
25.0%
1/4 • Number of events 1 • 2 years
|
0.00%
0/6 • 2 years
|
|
Gastrointestinal disorders
Constipation
|
25.0%
1/4 • Number of events 1 • 2 years
|
16.7%
1/6 • Number of events 1 • 2 years
|
|
Gastrointestinal disorders
Diarrhea
|
50.0%
2/4 • Number of events 2 • 2 years
|
16.7%
1/6 • Number of events 1 • 2 years
|
|
Gastrointestinal disorders
Dysphagia
|
0.00%
0/4 • 2 years
|
16.7%
1/6 • Number of events 1 • 2 years
|
|
Gastrointestinal disorders
Esophagitis
|
25.0%
1/4 • Number of events 1 • 2 years
|
0.00%
0/6 • 2 years
|
|
Gastrointestinal disorders
Mucositis, oral
|
25.0%
1/4 • Number of events 1 • 2 years
|
33.3%
2/6 • Number of events 3 • 2 years
|
|
Gastrointestinal disorders
Nausea
|
50.0%
2/4 • Number of events 2 • 2 years
|
33.3%
2/6 • Number of events 3 • 2 years
|
|
Gastrointestinal disorders
Vomiting
|
0.00%
0/4 • 2 years
|
16.7%
1/6 • Number of events 1 • 2 years
|
|
Gastrointestinal disorders
Gastrointestinal disorders-Other, Abdominal cramps
|
25.0%
1/4 • Number of events 1 • 2 years
|
0.00%
0/6 • 2 years
|
|
Investigations
Aspartate aminotransferase increase
|
25.0%
1/4 • Number of events 1 • 2 years
|
16.7%
1/6 • Number of events 2 • 2 years
|
|
Investigations
Alanine aminotransferase increase
|
25.0%
1/4 • Number of events 1 • 2 years
|
16.7%
1/6 • Number of events 1 • 2 years
|
|
Investigations
Creatine phosphokinase increase
|
0.00%
0/4 • 2 years
|
16.7%
1/6 • Number of events 1 • 2 years
|
|
Investigations
Weight loss
|
25.0%
1/4 • Number of events 1 • 2 years
|
0.00%
0/6 • 2 years
|
|
Musculoskeletal and connective tissue disorders
Muscle spasm or cramps
|
50.0%
2/4 • Number of events 2 • 2 years
|
66.7%
4/6 • Number of events 6 • 2 years
|
|
Musculoskeletal and connective tissue disorders
Myalgia
|
0.00%
0/4 • 2 years
|
50.0%
3/6 • Number of events 4 • 2 years
|
|
Musculoskeletal and connective tissue disorders
Bone pain
|
0.00%
0/4 • 2 years
|
16.7%
1/6 • Number of events 2 • 2 years
|
|
Injury, poisoning and procedural complications
Fracture
|
0.00%
0/4 • 2 years
|
33.3%
2/6 • Number of events 2 • 2 years
|
|
Nervous system disorders
Tremor
|
50.0%
2/4 • Number of events 2 • 2 years
|
16.7%
1/6 • Number of events 1 • 2 years
|
|
Nervous system disorders
Cognitive disturbance
|
0.00%
0/4 • 2 years
|
16.7%
1/6 • Number of events 1 • 2 years
|
|
Nervous system disorders
Dizziness
|
50.0%
2/4 • Number of events 2 • 2 years
|
0.00%
0/6 • 2 years
|
|
Nervous system disorders
Dysgeusia
|
50.0%
2/4 • Number of events 2 • 2 years
|
0.00%
0/6 • 2 years
|
|
Nervous system disorders
Headache
|
25.0%
1/4 • Number of events 1 • 2 years
|
0.00%
0/6 • 2 years
|
|
Nervous system disorders
Memory impairment
|
25.0%
1/4 • Number of events 1 • 2 years
|
0.00%
0/6 • 2 years
|
|
Nervous system disorders
Ataxia
|
25.0%
1/4 • Number of events 1 • 2 years
|
0.00%
0/6 • 2 years
|
|
Psychiatric disorders
Anxiety
|
75.0%
3/4 • Number of events 3 • 2 years
|
33.3%
2/6 • Number of events 4 • 2 years
|
|
Psychiatric disorders
Confusion
|
0.00%
0/4 • 2 years
|
16.7%
1/6 • Number of events 1 • 2 years
|
|
Psychiatric disorders
Depression
|
100.0%
4/4 • Number of events 4 • 2 years
|
50.0%
3/6 • Number of events 3 • 2 years
|
|
Psychiatric disorders
Insomnia
|
0.00%
0/4 • 2 years
|
16.7%
1/6 • Number of events 1 • 2 years
|
|
Skin and subcutaneous tissue disorders
Acne
|
0.00%
0/4 • 2 years
|
16.7%
1/6 • Number of events 1 • 2 years
|
|
Skin and subcutaneous tissue disorders
Skin & subcutaneous tissue disorders-others, Actinic keratosis
|
0.00%
0/4 • 2 years
|
50.0%
3/6 • Number of events 5 • 2 years
|
|
Skin and subcutaneous tissue disorders
Alopecia
|
25.0%
1/4 • Number of events 1 • 2 years
|
16.7%
1/6 • Number of events 1 • 2 years
|
|
Skin and subcutaneous tissue disorders
Purpura
|
0.00%
0/4 • 2 years
|
16.7%
1/6 • Number of events 1 • 2 years
|
|
Skin and subcutaneous tissue disorders
Dermatitis
|
0.00%
0/4 • 2 years
|
33.3%
2/6 • Number of events 3 • 2 years
|
|
Skin and subcutaneous tissue disorders
Pruritus
|
25.0%
1/4 • Number of events 3 • 2 years
|
16.7%
1/6 • Number of events 1 • 2 years
|
|
General disorders
Flu-like symptoms
|
25.0%
1/4 • Number of events 1 • 2 years
|
16.7%
1/6 • Number of events 1 • 2 years
|
|
General disorders
Fatigue
|
50.0%
2/4 • Number of events 2 • 2 years
|
100.0%
6/6 • Number of events 7 • 2 years
|
|
Eye disorders
Eye disorders-Others, change in vision
|
25.0%
1/4 • Number of events 1 • 2 years
|
0.00%
0/6 • 2 years
|
|
Eye disorders
Eye pain
|
50.0%
2/4 • Number of events 2 • 2 years
|
0.00%
0/6 • 2 years
|
|
Ear and labyrinth disorders
Ear pain (Otalgia)
|
25.0%
1/4 • Number of events 2 • 2 years
|
0.00%
0/6 • 2 years
|
|
Ear and labyrinth disorders
Hearing impaired
|
25.0%
1/4 • Number of events 1 • 2 years
|
0.00%
0/6 • 2 years
|
|
Renal and urinary disorders
Urinary frequency
|
0.00%
0/4 • 2 years
|
16.7%
1/6 • Number of events 1 • 2 years
|
|
Metabolism and nutrition disorders
Hyperglycemia
|
0.00%
0/4 • 2 years
|
16.7%
1/6 • Number of events 1 • 2 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neoplasms - Other, Malignant, skin, squamous cell carcinoma
|
0.00%
0/4 • 2 years
|
16.7%
1/6 • Number of events 1 • 2 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neoplasms - Other, Malignant, skin, basal cell carcinoma
|
0.00%
0/4 • 2 years
|
16.7%
1/6 • Number of events 1 • 2 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)-Others, Unspecified, skin
|
0.00%
0/4 • 2 years
|
16.7%
1/6 • Number of events 1 • 2 years
|
|
Blood and lymphatic system disorders
Other, bleeding (shoulder)
|
25.0%
1/4 • Number of events 3 • 2 years
|
0.00%
0/6 • 2 years
|
|
Infections and infestations
Bronchial infection
|
0.00%
0/4 • 2 years
|
33.3%
2/6 • Number of events 2 • 2 years
|
|
Infections and infestations
Upper respiratory tract infection
|
25.0%
1/4 • Number of events 1 • 2 years
|
0.00%
0/6 • 2 years
|
|
Infections and infestations
Skin infection
|
0.00%
0/4 • 2 years
|
16.7%
1/6 • Number of events 1 • 2 years
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
25.0%
1/4 • Number of events 1 • 2 years
|
16.7%
1/6 • Number of events 1 • 2 years
|
|
Respiratory, thoracic and mediastinal disorders
Allergic rhinitis
|
0.00%
0/4 • 2 years
|
16.7%
1/6 • Number of events 1 • 2 years
|
|
Vascular disorders
Hypertension
|
0.00%
0/4 • 2 years
|
50.0%
3/6 • Number of events 4 • 2 years
|
|
Surgical and medical procedures
Surgical and medical procedures-others, Moh's surgery for SCC
|
0.00%
0/4 • 2 years
|
16.7%
1/6 • Number of events 1 • 2 years
|
|
Surgical and medical procedures
Surgical and medical procedures
|
0.00%
0/4 • 2 years
|
16.7%
1/6 • Number of events 1 • 2 years
|
|
Surgical and medical procedures
Surgical and medical procedures-others Cyst Removal
|
0.00%
0/4 • 2 years
|
16.7%
1/6 • Number of events 1 • 2 years
|
Additional Information
Anne Lynn S. Chang/ Associate Professor of Dermatology
Stanford University
Phone: 650-723-6316
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place